Compare RGTI & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGTI | XENE |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United States | Canada |
| Employees | 164 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.2B |
| IPO Year | N/A | 2014 |
| Metric | RGTI | XENE |
|---|---|---|
| Price | $16.49 | $63.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $30.78 | ★ $68.55 |
| AVG Volume (30 Days) | ★ 19.0M | 1.1M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $311,000.00 |
| Revenue This Year | $225.06 | N/A |
| Revenue Next Year | $99.56 | $2,496.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.53 | $32.78 |
| 52 Week High | $58.15 | $72.66 |
| Indicator | RGTI | XENE |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.46 |
| Support Level | N/A | $52.40 |
| Resistance Level | N/A | $72.66 |
| Average True Range (ATR) | 0.00 | 1.96 |
| MACD | 0.00 | -0.58 |
| Stochastic Oscillator | 0.00 | 46.34 |
Rigetti Computing Inc builds quantum computers and the superconducting quantum processors that power them. The Company sells 9-qubit to 108-qubit quantum computing systems under the Novera and Cepheus trade names. Through the Rigetti Quantum Cloud Services (QCS) platform, the Company's machines can be integrated into any public, private or hybrid cloud. The Company also operates in Fremont, California; London, United Kingdom; Adelaide, Australia; British Columbia, Canada and Mumbai, India. The Company's revenue is derived from operations in the United States and the United Kingdom.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.